SCHEMBL339989

SCHEMBL339989

CP(=O)(O)CC(=O)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7823406 0.78
SCHEMBL11501421 0.78 GABRR1 (0.38)
SCHEMBL9862949 0.72
SCHEMBL11419595 0.72 ANPEP (0.33)
SCHEMBL4315775 0.72 TSHR (0.42)
SCHEMBL11424753 0.72 GABBR2 (0.42)
SCHEMBL27291042 0.70
SCHEMBL9281366 0.70 KDM4E (0.32)
Aminomethyl(Methyl)Phosphinic Acid SCHEMBL8899845 0.70
Methyl Phosphonate SCHEMBL15419630 0.69 GLRA1 (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190167632-A1 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) MUELLER WOLFGANG S (US) 2019-06-06 US claimed
US-20190125779-A1 PHARMACEUTICAL COMPOSITIONS UNIVERSITY OF HOUSTON SYSTEM (US) 2019-05-02 US claimed
US-10238622-B2 Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) THE REGENTS OF THE UNIVERSITY OF NEW MEXICO 2019-03-26 US claimed
US-20170042929-A9 Methods of Treating Neurological Diseases UNIVERSITY OF HOUSTON 2017-02-16 US claimed
WO-2016109624-A1 PHARMACEUTICAL COMPOSITIONS UNIVERSITY OF HOUSTON SYSTEM (US) 2016-07-07 WO claimed
US-20150051166-A1 Methods of Treating Neurological Diseases ZIBURKUS JOKUBAS (US) 2015-02-19 US claimed
WO-2014028883-A1 METHODS OF TREATING OF NEUROLOGICAL DISEASES UNIVERSITY OF HOUSTON (US) 2014-02-20 WO claimed
EP-2593104-A2 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) Müller, Prof. Dr., Wolfgang (DE) 2013-05-22 EP claimed
US-20120115919-A1 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) THE REGENTS OF THE UNIVERSITY OF NEW MEXICO 2012-05-10 US claimed
WO-2011113904-A1 MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2011-09-22 WO claimed
CN-1413104-A New (aminopropyl) methylphosphinic acids ASTRAZENECA AB (SE) 2003-04-23 CN claimed
EP-1239843-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS AstraZeneca AB (SE) 2002-09-18 EP claimed
WO-2001041743-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS ASTRAZENECA AB (SE) 2001-06-14 WO claimed
US-6117908-A Use of GABAB receptor agonists as reflux inhibitors ASTRA AKTIEBOLAG (SE) 2000-09-12 US claimed
EP-0936906-A1 REFLUX INHIBITORS Astra Aktiebolag (SE) 1999-08-25 EP claimed
WO-1998011885-A1 REFLUX INHIBITORS ASTRA AKTIEBOLAG (SE) 1998-03-26 WO claimed
US-5567840-A AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS CIBA-GEIGY CORPORATION (US) 1996-10-22 US claimed
EP-0399949-B1 Substituted aminoalkylphosphinic acids CIBA GEIGY AG (CH) 1995-04-12 EP claimed
US-5281747-A Pharmaceuticals CIBA-GEIGY CORPORATION (US) 1994-01-25 US claimed
EP-0399949-A1 Substituted aminoalkylphosphinic acids CIBA-GEIGY AG (CH) 1990-11-28 EP claimed